Market Overview:
The global bendamustine for injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for better treatment options, and growing awareness about available treatments. Based on type, the global bendamustine for injection market is segmented into 25mg injection, 100mg injection, and other. The 100mg injection segment is expected to account for the largest share of the global market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. Based on application, the global bendamustine for injection market is divided into chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL). The CLL segment accounted for the largest share of this market in 2017 and is projected to grow at a CAGR of xx% duringthe forecast period from2018to2030. Geographically, North America dominates this market followed by Europeand Asia Pacific .
Product Definition:
Bendamustine for Injection is a cytotoxic agent used to treat certain types of cancer.
25mg Injection:
25mg Injection is a generic name for the benzodiazepine drug class. It is also known as "Bendamustine". The generic form of this medication was approved by the U.S. FDA in 1996 and 1997 respectively and it has been on sale since then till now (more than 15 years).
100mg Injection:
Bendamustine is an injectable form of the drug, which is used for the treatment of multiple myeloma and lymphomas. It works by targeting a protein that causes cancer cells to multiply rapidly. The medicine has no effect on healthy cells and does not cause bone marrow suppression or blood clotting.
The medicine was approved by the U.
Application Insights:
The chronic lymphocytic leukemia segment dominated the global bendamustine for injection market in 2017, owing to the increasing incidence of this disease. Chronic Lymphocytic Leukemia (CLL) is a type of blood cancer which affects mostly white males aged 55 years and above. The disease is characterized by an abnormal accumulation of lymphocytes in the body leading to high-grade B-cell proliferation and bone marrow infiltration resulting in shortness of breath, anemia and weight loss.
According to data published by CDC, U.S.
Regional Analysis:
Asia Pacific dominated the global market in 2017. This can be attributed to high unmet clinical needs, availability of effective treatment methods, rising disposable income and growing awareness about early diagnosis. Moreover, increasing investments by major players for R&D of novel drug molecules is expected to drive the growth over the forecast period.
In addition, favorable government initiatives such as “Make in India†campaign by Government of India are expected to create ample growth opportunities for domestic manufacturers thereby driving down prices and making it more accessible & affordable for patients across India. In addition, increasing healthcare expenditure coupled with a rise in per capita income is anticipated to further fuel demand over the next eight years.
North America region followed Asia Pacific with a significant share owing to factors such as well-established healthcare infrastructure.
Growth Factors:
- Increasing incidence of lymphoma and leukemia across the globe is expected to drive the demand for bendamustine over the forecast period.
- The increasing number of clinical trials for bendamustine is also anticipated to propel market growth during the forecast period.
- Availability of generic versions is expected to reduce treatment costs, which would further boost market growth over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Bendamustine for Injection Market Research Report
By Type
25mg Injection, 100mg Injection, Other
By Application
Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
By Companies
Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, Miracalus Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
188
Number of Tables & Figures
132
Customization Available
Yes, the report can be customized as per your need.
Global Bendamustine for Injection Market Report Segments:
The global Bendamustine for Injection market is segmented on the basis of:
Types
25mg Injection, 100mg Injection, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Eisai
- Eagle Pharmaceuticals
- MundiPharma
- Mylan
- Natco Pharma
- Emcure
- Miracalus Pharma
Highlights of The Bendamustine for Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 25mg Injection
- 100mg Injection
- Other
- By Application:
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bendamustine for Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bendamustine is a chemotherapy drug used to treat certain types of cancer. Bendamustine is injected into the tumor and then slowly released over time. This helps to kill the cancer cells.
Some of the key players operating in the bendamustine for injection market are Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, Miracalus Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bendamustine for Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bendamustine for Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bendamustine for Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bendamustine for Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bendamustine for Injection Market Size & Forecast, 2020-2028
4.5.1 Bendamustine for Injection Market Size and Y-o-Y Growth
4.5.2 Bendamustine for Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 25mg Injection
5.2.2 100mg Injection
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Chronic Lymphocytic Leukemia
6.2.2 Multiple Myeloma
6.2.3 Non-Hodgkin's Lymphoma
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bendamustine for Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bendamustine for Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 25mg Injection
9.6.2 100mg Injection
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Chronic Lymphocytic Leukemia
9.10.2 Multiple Myeloma
9.10.3 Non-Hodgkin's Lymphoma
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 25mg Injection
10.6.2 100mg Injection
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Chronic Lymphocytic Leukemia
10.10.2 Multiple Myeloma
10.10.3 Non-Hodgkin's Lymphoma
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 25mg Injection
11.6.2 100mg Injection
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Chronic Lymphocytic Leukemia
11.10.2 Multiple Myeloma
11.10.3 Non-Hodgkin's Lymphoma
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 25mg Injection
12.6.2 100mg Injection
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Chronic Lymphocytic Leukemia
12.10.2 Multiple Myeloma
12.10.3 Non-Hodgkin's Lymphoma
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 25mg Injection
13.6.2 100mg Injection
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Chronic Lymphocytic Leukemia
13.10.2 Multiple Myeloma
13.10.3 Non-Hodgkin's Lymphoma
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bendamustine for Injection Market: Competitive Dashboard
14.2 Global Bendamustine for Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Eisai
14.3.3 Eagle Pharmaceuticals
14.3.4 MundiPharma
14.3.5 Mylan
14.3.6 Natco Pharma
14.3.7 Emcure
14.3.8 Miracalus Pharma
